PROVEN EFFICACY

Proven efficacy in patients with SLE1-4

In Phase III trials, response was defined as ≥4-point reduction in SELENA-SLEDAI score, and no new BILAG A or ≤1 new BILAG B organ domain scores, and <0.30-point increase in PGA score at Week 52

Superior disease activity reduction when added to standard therapy vs. standard therapy alone1-4

The difference in SRI-4 response rates did not reach statistical significance at Week 76, a secondary endpoint.

These reductions were primarily related to improvements in the mucocutaneous, musculoskeletal, and immunologic organ domains.

SELENA-SLEDAI - Safety of Estrogens in Lupus Erythematosus: National Assessment Version of the Systemic Lupus Erythematosus Disease Activity Index.
BILAG - British Isles Lupus Assessment Group.
PGA - Physician’s Global Assessment.

ADVERSE REACTIONS

ADVERSE REACTIONS IN CLINICAL TRIALS

Adverse reactions in ≥3% of patients receiving BENLYSTA intravenous 10 mg/kg + standard therapy and ≥1% more frequently than in those receiving placebo + standard therapy in the 52-week Phase II trial, BLISS-52, and BLISS-76

  Preferred Term BENLYSTA 10 mg/kg +
Standard Therapy
(n=674)
%
Placebo + Standard Therapy
(n=675)
%
 
  Nausea 15 12  
  Diarrhea 12 9  
  Pyrexia 10 8  
  Nasopharyngitis 9 7  
  Bronchitis 9 5  
  Insomnia 7 5  
  Pain in extremity 6 4  
  Depression 5 4  
  Migraine 5 4  
  Pharyngitis 5 3  
  Cystitis 4 3  
  Leukopenia 4 2  
  Gastroenteritis viral 3 1  

The safety profile for BENLYSTA SC + standard therapy was consistent with that of BENLYSTA IV + standard therapy, with the exception of local injection site reactions.

BENLYSTA has 7 years of in-market experience.1

DELIVERY OPTIONS

Multiple administration options to meet your patients’ needs1

Subcutaneous injection:
200 mg once-weekly
BENLYSTA SC is supplied as:

200 mg/mL single-dose
prefilled autoinjector

200 mg/mL single-dose
prefilled glass syringe

1-hour IV infusion: 10 mg/kg every 4 weeks after the first 3 doses (10 mg/kg every 2 weeks)
BENLYSTA IV is supplied as:

120 mg in a 5-mL single-dose vial
400 mg in a 20-mL single-dose vial

Useful tools to support your patients

Find the vial combination that
helps minimize product waste.

Calculate patients’
infusion dates.

Chat